instrumental enzymes: From Natural Selection to AI Customization

In a biotech lab setup, core enzymes like restriction endonucleases, DNA polymerases, and T4 ligases are the fundamental reagents that support all kinds of experiments. Throughout processes like genetic engineering, molecular cloning, DNA sequencing, PCR amplification, and gene editing, each enzyme has its own role: restriction endonucleases handle cutting nucleic acids and are known as 'molecular scissors'; T4 ligase stitches DNA fragments together, acting as a 'molecular needle and thread'; DNA polymerase drives nucleic acid amplification, serving as the 'replication engine'.

The discovery and iteration of these enzymes have given humans the ability to precisely control nucleic acid sequences at the molecular level. From constructing the first recombinant E. coli to launching commercial gene therapy drugs; from the first isolation of Type II restriction enzymes to the advent of CRISPR gene editing systems, continual improvements in these enzymes have driven the development of biotechnology. Nowadays, breakthroughs in AI-based protein design are helping enzyme development move beyond the lengthy screening of natural strains and traditional directed evolution methods, entering an era where sequences can be customized on demand and performance can be rapidly iterated.

1. Instrumental enzymes: the underlying infrastructure for biotechnology research and development

Tool-based enzymes are fundamental core materials for genetic engineering and molecular biology experiments, and the vast research and industrial demand has fueled a continuously expanding global market. According to public forecast data from multiple market research institutions, the global tool enzyme market has maintained stable growth over the long term: PCR enzymes and various DNA polymerases hold the largest market share and are widely used in clinical molecular diagnostics and basic life sciences research; Restriction endonuclease is a core consumable for molecular cloning and DNA fingerprinting analysis; Ligases and various nucleic acid modification enzymes support key experimental steps such as DNA fragment splicing and nucleic acid end modification. The Asia-Pacific region leads the global growth market, driven by increased investment in basic life sciences research in China, India, and the continued expansion of the biopharmaceutical industry chain.

Among all tool enzyme systems, type II restriction endonucleases are the most basic and widely used category of molecular cloning. They can specifically identify fixed palindromic sequences of double-stranded DNA and precisely cut them, serving as the core cutting tool for nucleic acid manipulation. In 1970, Smith and Wilcox isolated the first type II restriction endonuclease with site-specific cleavage activity from Haemophilus influenzae (then named HindII); Over the following decades, researchers identified over 4,000 naturally restricted endonucleases from massive microbial strains, forming the core foundation of modern molecular cloning technology.

Naturally derived instrumental enzymes generally have unavoidable performance shortcomings that directly limit experimental stability and industrial application:

Thermal stability defects: Standard PCR denaturation steps require enzymes to withstand repeated cycles at 94–98°C high temperatures; The vast majority of wild-type DNA polymerases from mesothermic microorganisms (such as E. coli) are rapidly inactivated at this temperature. Although Taq polymerase isolated from thermophiles (such as Thermus aquaticus) is naturally heat-resistant, its lack of 3'→5' exonuclease calibration activity results in low fidelity and difficulty meeting the requirements for high-precision amplification.

Insufficient cleavage specificity: Most restriction endonucleases have asterisk-level activity (non-specific cleavage): when glycerol concentration is too high, buffer components/ions are abnormal, or enzyme dosage is too large, the enzyme may deviate from its inherent recognition sequence and cut DNA, causing vector self-linking and target fragment fragmentation, seriously interfering with molecular cloning experiments.

Substrate compatibility limitations: Different tool enzymes have inherent preferences for nucleic acid sequences and DNA secondary structures, which directly reduce catalytic reaction efficiency;

High production and preparation threshold: Some natural tool enzymes have low expression levels in E. coli hosts, making them prone to forming inclusions, making purification processes complex and increasing overall usage costs.

2. The Dilemma of Traditional Enzyme Development: Dual Bottlenecks in Strain Screening and Iterative Modification

For a long time, the mining and performance optimization of tool enzymes have faced significant technical bottlenecks and industry commercial barriers.

Early tool enzyme resources relied entirely on screening natural microbial strains rather than designing sequences from scratch with specific targets. Researchers had to isolate and cultivate microorganisms on a large scale, then verify each strain's nucleic acid cleavage, polymerization, and ligation catalytic activities one by one. This approach is limited by the diversity of microorganisms in nature, resulting in low efficiency and poor targeting when screening for desired functional enzymes, making it difficult to meet the diversified and customized experimental needs of modern biotechnology.

Even when a natural enzyme with basic activity is obtained through screening, the subsequent performance optimization process remains lengthy. Traditional directed evolution relies on random mutations to build large-scale mutant libraries, and a single round of screening typically takes 6 to 12 months; industrial-grade stable enzymes often require multiple rounds of mutation and screening. For a high-fidelity DNA polymerase with 300 amino acids, a single point mutation can generate thousands of variants, while combined double-site mutations can reach millions of sequences. Limited by the throughput of high-throughput screening equipment, directed evolution can only explore local sequence spaces, making it difficult to find mutants with more balanced overall performance.

Various enzymatic performance metrics often have trade-offs, making simultaneous optimization challenging: improving the fidelity of DNA polymerases usually reduces the nucleic acid amplification rate; enhancing the enzyme's thermal stability may weaken the flexibility at the catalytic site and decrease substrate binding efficiency. Relying on manual experience to adjust mutation plans makes it difficult to find a balanced solution among multiple conflicting performance indicators.

3. AI Reshapes the Tool Enzyme Development Paradigm: From Passive Resource Acquisition to Active Function Creation

AI Enzyme Design Hexagon

AI computational technologies represented by the AlphaFold series of models are transforming the way we develop enzyme tools: shifting from passive screening that relies on natural microbial resources to an active design approach based on computational predictions and custom protein sequences.

The 2024 Nobel Prize in Chemistry was awarded to David Baker, Demis Hassabis, and John Jumper, recognizing their pioneering contributions in atomic-level protein structure prediction and computationally driven de novo protein design. High-precision 3D protein analysis technology provides the core computational support for rational enzyme remodeling. In particular, AlphaFold2 enables near-atomic accuracy in static protein structure prediction, giving a precise structural foundation for targeted mutations. Research relying on AlphaFold 3 has already achieved rational remodeling of the light-activated restriction endonuclease MagMboI, screening a mutant variant called MagMboI-plus. This variant has only been validated in yeast cells; under blue-light induction, its in vivo DNA cleavage activity slightly increases and can induce genomic rearrangement. This represents a milestone in the development of light-controlled genome editing tools at the lab level, but no testing has yet been done in mammalian cells.

Profluent’s OpenCRISPR-1 is a notable advancement in AI-de novo designed CRISPR-Cas proteins, with results published in *Nature*. Compared to natural SpCas9, this protein has over 400 amino acid mutations and differs from any known natural Cas homolog by more than 180 amino acids. OpenCRISPR-1 can achieve stable gene editing in human cells, with editing efficiency comparable to or slightly better than wild-type SpCas9, while off-target cutting risks are significantly reduced. It’s a prime example of a gene editing effector protein designed by AI models independently of the natural Cas backbone.

In academia, the AiCE (AI-informed Constraint Engineering) general protein optimization framework is being developed. This integrates protein inverse folding models with dual constraints from protein structure and species evolution. It can efficiently predict beneficial mutation sites without retraining dedicated models for each enzyme task, and has been applied to base editors and various nucleases. On publicly available protein engineering benchmark datasets, AiCE's accuracy for functional mutation prediction ranges from 11% to 88%, outperforming traditional random mutagenesis screening and single-homology modeling approaches.

Together, these AI tech achievements are paving a new R&D path: enzyme engineering is gradually moving away from natural resource screening and trial-and-error methods, toward a predictive, highly iterative, and sequence-programmable standardized protein engineering system.

3.1 Structure Prediction: AI Explains the Fundamentals of Protein Function

The AlphaFold series of models have overcome the challenge of accurately predicting protein 3D structures. They can clearly reveal how enzymes interact with DNA substrates at binding pockets and the spatial configuration of catalytic active sites. Researchers can use these structures to pinpoint key amino acid residues that affect thermal stability, cleavage specificity, and substrate affinity, providing a computational basis for targeted rational mutations.

3.2 Targeted Rational Engineering: Upgrading the Performance of Natural Enzymes

Using AI structure prediction results, there’s no need to create massive random mutation libraries. By only modifying core functional sites, natural enzymes’ weaknesses can be quickly optimized. A typical example is the MagMboI light-controlled endonuclease modification study, where just targeted mutations at cleavage sites led to a slight increase in cutting activity in yeast, significantly shortening the traditional directed evolution screening cycle.

3.3 De Novo Protein Design: Creating Entirely New Enzymes Without Natural Templates

AI de novo design technology, represented by OpenCRISPR-1, is no longer limited to modifying natural protein scaffolds. Using RFdiffusion to generate scaffolds, it builds entirely new 3D protein structures from scratch. Then, ProteinMPNN generates amino acid sequences matching the new scaffolds, creating novel tool enzymes that don’t exist in nature but meet experimental requirements.

3.4 Universal Algorithm Framework AiCE: Standardized Optimization for Multiple Enzyme Types

The AiCE framework isn’t limited to a single type of nuclease. It applies to various protein engineering tasks like base editors, restriction endonucleases, DNA polymerases, and ligases. It sets up a universal mutation prediction workflow, making AI-driven modifications easier across different enzyme types.

4. The Full-Chain Capability System of AI-Empowered Tool Enzymes

Computational Design to Industrial Production

Relying on a complete AI-driven protein de novo design technology system, the development of tool enzymes has formed a closed-loop R&D process from defining functional targets to industrial production validation.

Upstream protein design phase: After researchers clarify the target performance requirements (such as high-fidelity DNA polymerases or thermostable restriction endonucleases), the RFdiffusion backbone generation tool can independently construct brand-new protein 3D backbones suited to the desired catalytic function, free from the constraints of natural protein structures. The ProteinMPNN sequence optimization tool can generate thousands of high-solubility, high-thermal-stability candidate amino acid sequences, far exceeding the scale of a few hundred sequences typical of traditional screening methods. The AlphaFold structure prediction model builds 3D models of the enzyme-nucleic acid substrate complex. By virtual screening, it predicts cutter site binding ability, molecular binding affinity, and protein thermal stability parameters. The best-selected sequences can be directly synthesized and enter the wet-lab activity validation phase.

Downstream experimental validation phase: The automated high-throughput experimental platform can simultaneously test the activity and specificity of hundreds of candidate proteins, quickly quantifying the catalytic performance of various variants. All measured activity and stability data are fed back to the AI models in real time, updating model parameters and triggering the next round of sequence optimization, forming a complete closed loop: "sequence design → gene synthesis → protein expression → activity testing → data feedback → iterative optimization." At the practical level, intelligent enzyme analysis systems combined with AI algorithms can predict optimal enzyme buffer conditions and reaction durations, dynamically optimizing experimental parameters, effectively improving in vitro enzyme reaction efficiency, and connecting computational design with lab operations.

In the industrial production phase, large language model-supported synthetic biology platforms automatically optimize codon preferences and screen expression host strains for the AI-designed tool enzyme genes. At the same time, fermentation temperature, inducer concentration, and protein purification processes are iteratively optimized. AI-designed proteins from small-scale lab experiments can be quickly scaled up to industrial production, achieving end-to-end integration from algorithmic sequence design to finished reagent delivery.

5. Industrial value of AI tool enzymes: Continuously expanding niche market tracks.

Interlocking Biotech Gear Ecosystem

AI technology has significantly shortened the development cycle of tool enzymes, reducing the traditional multi-year modification process to just a few months, and is continuously expanding the boundaries of the customized tool enzyme market. According to calculations from multiple market institutions, the global traditional tool enzyme market has maintained stable growth over the long term. When factoring in the additional demand for AI-customized new tool enzymes, including gene-editing-specific nucleases, synthetic biology pathway-adapting ligases, and high-temperature-resistant polymerases for molecular diagnostics, the market for this segment could potentially expand to the scale of tens of billions of yuan in the long term. The ultimate market size will depend on the commercialization pace of downstream biopharmaceutical and synthetic biology industries.

AI-designed tool enzymes are simultaneously promoting the technological upgrade of the entire downstream industry chain:

- Gene therapy: AI-optimized high-fidelity gene-editing nucleases can reduce off-target cutting risks and improve the clinical safety of in vivo gene modification;

- Synthetic biology: Tool enzyme components customized for specific metabolic pathways can increase the catalytic efficiency of biosynthesis in microorganisms;

- Molecular diagnostics: DNA polymerases optimized for inhibitor resistance can simplify clinical sample nucleic acid pre-processing, reducing both consumables and time costs.

The high demand for performance tool enzymes from downstream industries, the continuous iteration of AI protein design algorithms, and ongoing industry capital investment create a positive feedback loop, accelerating the transition of AI tool enzymes from basic lab research to commercial reagents. However, there are still multiple practical constraints on industry implementation: AI-predicted protein structures may deviate from actual folding in cells, large-scale synthesis of entirely new proteins remains costly, and biopharmaceutical editing enzymes must pass strict clinical regulatory approvals. Therefore, short-term large-scale commercialization across all categories still requires corresponding technological advancements.

6. Conclusion: The Leap in R&D Models from Natural Selection to Computational Creation

From naturally sourced bacterial restriction endonucleases to AI-designed OpenCRISPR-1 gene editing proteins, the development of tool enzymes has completed a three-stage path: screening natural microbial resources, rational targeted modification of natural enzymes, and the AI-based creation of entirely new proteins.

The core factor driving industry iteration is the significant improvement in the underlying design efficiency of tool enzyme development. AI is shifting enzyme engineering from an experience-driven experimental model that heavily relies on strain screening, random mutations, and trial-and-error, to a standardized protein engineering R&D system where predictions are quantitative, iteration cycles are controllable, and sequences can be programmatically designed.

With AI computational design capabilities, researchers can create tailored tool enzymes for specific experimental needs: restriction endonucleases that match particular DNA recognition sequences, DNA polymerases that withstand extreme heat amplification conditions, and highly efficient DNA ligases suitable for synthetic biology metabolic pathways. These customized molecular tools will continue to expand the technical boundaries of genetic engineering, molecular diagnostics, synthetic biology, and gene therapy. What used to rely entirely on naturally occurring microorganisms for nucleic acid enzymes can now be designed, modified, and produced by humans according to experimental needs, with AI computational technology at the core of this transformation in R&D models.